Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin. 2020

Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
Departamento de Investigacion en Polimeros y Materiales, Universidad de Sonora, Bulevar Luis Encinas y Rosales s/n, Colonia Centro, Hernosillo, Sonora 83000, Mexico.

Doxorubicin (Dox) is the most widely used chemotherapeutic agent and is considered a highly powerful and broad-spectrum for cancer treatment. However, its application is compromised by the cumulative side effect of dose-dependent cardiotoxicity. Because of this, targeted drug delivery systems (DDS) are currently being explored in an attempt to reduce Dox systemic side-effects. In this study, DDS targeting hepatocellular carcinoma (HCC) has been designed, specifically to the asialoglycoprotein receptor (ASGPR). Dox-loaded albumin-albumin/lactosylated (core-shell) nanoparticles (tBSA/BSALac NPs) with low (LC) and high (HC) crosslink using glutaraldehyde were synthesized. Nanoparticles presented spherical shapes with a size distribution of 257 ± 14 nm and 254 ± 14 nm, as well as an estimated surface charge of -28.0 ± 0.1 mV and -26.0 ± 0.2 mV, respectively. The encapsulation efficiency of Dox for the two types of nanoparticles was higher than 80%. The in vitro drug release results showed a sustained and controlled release profile. Additionally, the nanoparticles were revealed to be biocompatible with red blood cells (RBCs) and human liver cancer cells (HepG2 cells). In cytotoxicity assays, Dox-loaded nanoparticles decrease cell viability more efficiently than free Dox. Specific biorecognition assays confirmed the interaction between nanoparticles and HepG2 cells, especially with ASGPRs. Both types of nanoparticles may be possible DDS specifically targeting HCC, thus reducing side effects, mainly cardiotoxicity. Therefore, improving the quality of life from patients during chemotherapy.

UI MeSH Term Description Entries
D007785 Lactose A disaccharide of GLUCOSE and GALACTOSE in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry. Anhydrous Lactose,Lactose, Anhydrous
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses

Related Publications

Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
April 2017, Colloids and surfaces. B, Biointerfaces,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
January 2012, International journal of nanomedicine,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
October 2018, Molecules (Basel, Switzerland),
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
October 2010, Journal of nanoscience and nanotechnology,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
January 2020, Drug design, development and therapy,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
November 2014, Nanomedicine : nanotechnology, biology, and medicine,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
April 2016, Journal of controlled release : official journal of the Controlled Release Society,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
March 2009, Biomaterials,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
June 2013, Journal of controlled release : official journal of the Controlled Release Society,
Nayelli Guadalupe Teran-Saavedra, and Jose Andrei Sarabia-Sainz, and Enrique Fernando Velázquez-Contreras, and Gabriela Ramos-Clamont Montfort, and Martín Pedroza-Montero, and Luz Vazquez-Moreno
November 2017, Drug delivery,
Copied contents to your clipboard!